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Active site-directed molecular probeBackground: Synthetic probes that mimic natural substrates can enable the detection of enzymatic activities
in a cellular environment. One area where such activity-based probes have been applied is the ubiquitin–
proteasome pathway, which is emerging as an important therapeutic target. A family of reagents has been
developed that speciﬁcally label deubiquitylating enzymes (DUBs) and facilitate characterization of their in-
hibitors. Scope of review: Here we focus on the application of probes for intracellular DUBs, a group of speciﬁc
proteases involved in the ubiquitin proteasome system. In particular, the functional characterization of the
active subunits of this family of proteases that speciﬁcally recognize ubiquitin and ubiquitin-like proteins
will be discussed. In addition we present the potential and design of activity-based probes targeting kinases
and phosphatases to study phosphorylation. Major conclusions: Synthetic molecular probes have increased
our understanding of the functional role of DUBs in living cells. In addition to the detection of enzymatic ac-
tivities of known members, activity-based probes have contributed to a number of functional assignments of
previously uncharacterized enzymes. This method enables cellular validation of the speciﬁcity of small mol-
ecule DUB inhibitors. General signiﬁcance: Molecular probes combined with mass spectrometry-based prote-
omics and cellular assays represent a powerful approach for discovery and functional validation, a concept
that can be expanded to other enzyme classes. This addresses a need for more informative cell-based assays
that are required to accelerate the drug development process. This article is part of a Special Issue entitled:
Ubiquitin Drug Discovery and Diagnostics.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The last two decades have witnessed the development and ap-
plication of activity based probes for the detection of enzymatic ac-
tivities related to a wide range of protein post-translational
modiﬁcations (PTMs). These tools have allowed for the detection
of many enzymatic activities in relation to conjugation and
deconjugation of PTMs. The greatest success and widest application
of this approach have probably been found within the ubiquitinnosine diphosphate; ATP, Adenosin
ase; HAUbBr2, HA-tagged ubiquitin e
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rights reserved.proteasome pathway [1]. The ubiquitin proteasome system (UPS)
consists of three different elements with partially opposing,
but complementary roles; the ubiquitin conjugating cascade, the
deubiquitylating enzymes and the proteasome complex (Fig. 1).
The ubiquitin conjugating cascade of enzymes (E1, E2, E3 and E4)
is responsible for conjugating ubiquitin (Ub)/ubiquitin-like proteins
(Ubls) to other proteins as signaling molecules in several biological
processes [2,3]. The deubiquitylating enzymes (DUBs) are responsi-
ble for removing, trimming or editing the Ub/Ubl modiﬁcationse triphosphate; DUB, Deubiquitylating enzyme; E1, Ubiquitin activating enzyme; E2,
thyl bromide; HAUbVME, HA-tagged ubiquitin vinyl methyl ester; HAUbVS, HA-tagged
slational Modiﬁcation; PTP, Protein Tyrosine Phosphatase; SDS-PAGE, Sodium dode-
quitin; Ubl, Ubiquitin-like protein; UCH-L1, Ubiquitin carboxyl terminal hydrolase iso-
rboxyl terminal hydrolase isozyme L5; USP7, Ubiquitin speciﬁc processing protease 7
.
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Fig. 1. Schematic illustration key components of ubiquitin proteasome system; from the activation of newly transcribed ubiquitin (Ub), modiﬁcation of proteins with Ub by the Ub
enzyme cascade and deubiquitinating enzymes to the fate of ubiquitinated proteins.
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three different proteolytically active subunits β1, β2 and β5, de-
grades the majority of soluble proteins within the cell following
polyubiquitylation [4]. The UPS not only enables the targeted de-
struction of proteins no longer required by the cell, but also enables
the selective deactivation of signaling molecules, removal of patho-
genic proteins and production of peptides for presentation to the
immune system. The entire pathway comprises close to 1000
genes, is vital for many normal cellular functions and is frequently
disrupted in cellular pathologies [5,6].
A likely explanation for the remarkable success of development of
activity-based probes in the UPS when compared to small molecule
probes related to other PTMs, is the ability to target cysteine and
threonine proteases successfully by covalent inhibition. These repre-
sent the major enzymatic activities of DUBs and the proteasome re-
spectively. Improved recognition of the protein-based ubiquitin and
peptide-derived proteasome probes as compared with small mole-
cule based probes may also contribute. The generation of activity
based probes for the ubiquitin pathway as important tools to obtain
insights into the ubiquitin proteasome system has been reviewed
previously [7–10]. The focus of this review is the application of
activity-based probes in the context of inhibitor development and
characterization. This process represents a critical step in arriving at
a better understanding of fundamental cellular processes and enables
the development of novel targeted therapeutic agents.2. Activity-based proteomics probes
Activity-based probes (ABPs) are deﬁned by their ability to target
subsets of a complex proteome based on labeling of speciﬁc enzyme
classes in a covalent fashion. The incorporation of speciﬁc tags for de-
tection and enrichment allows for visualization and further analysis
for example by tandemmass spectrometry. The ABP approach is highly
complementary to mass spectrometry-based proteomics due to the
ability to enrich for speciﬁcally captured substrates with the aid of an
afﬁnity tag. This also distinguishes the method from the use of
radiolabeled covalent inhibitors that support detection but not afﬁnity
enrichment. A critical parameter is also the choice of reactive group for
covalent labeling of the target enzyme at or close to the enzyme active
site. Depending on the mechanism of enzymatic catalysis differentreactive groups can be chosen for covalent capture. The alkylation of
nucleophilic residues (Cys, Ser, Thr) present in protease active sites
by reactive electrophiles has been a very successful realization of this
method. The utility of ABPs is particularly evident in the study of en-
zyme systems involved in the attachment and removal of PTMs. Due
to the enzyme active site chemistries involved ABP development
has been generally more fruitful for the targeting of deconjugating en-
zymes that usually contain strong nucleophiles at their active sites
when compared to the respective ligases/transferases.3. Proteasome active site probes
The discovery and development of proteasome inhibitors have
been previously covered by comprehensive reviews [10,11]. Here,
we will therefore only give a brief introduction to the proteasome
complex and proteasome active site probes.
The proteolytically active sites of the proteasome complex are lo-
cated on distinct subunits (for example β1, β2 and β5 in the constitu-
tive proteasome) and this is reﬂected by the labeling pattern obtained
by active site-directed proteasome probes [12]. The three subunits re-
sponsible for proteolysis also correspond to different activity proﬁles
with respect to substrate speciﬁcity which were named after proto-
typic proteases: chymotrypsin-like activity for β5 (CT-L), trypsin-
like activity for β2 (T-L) and petidylglutamyl peptide hydrolyzing-
like (PGPH-L) activity (also referred to as caspase-like) for β1 [13].
Exchange of the active subunits with close homologues can be in-
duced in immune cells [14] and the thymus [15]. This allows for the
tuning of the peptide repertoire produced by proteasomal proteolysis,
which underscores the importance of presentation of these peptides
(after further processing steps) in immune surveillance.
Proteolytically active subunits of the proteasome have been
targeted by probes based on peptide scaffolds bearing a C-terminal
electrophile (Fig. 2). The most popular designs have been based on
the trileucine vinylsulfone (L3VS) sub-structure and on functionalized
epoxomicin derivatives. Proﬁling with these probes is enabled by de-
tection with dansyl [16] and biotin [17,18] tags and with strong
ﬂuorophores [19,20] as well as by radiolabels [12,21]. Alternatively,
a two step protocol can be applied whereby the tag is attached in a
bioorthogonal ligation step following labeling of active proteasome
subunits in a cell lysate [22]. This selective ligation is possible through
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Fig. 2. Design of proteasome active site probes; peptide-based probes for labeling of ac-
tive proteasome subunits have been based on trileucine vinyl sulfones (A), the
epoxyketone containing epoxomicin (B) and a belacostin A based derivative Dansyl-
KF33955 (C). Abbreviations: Ahx: 6-aminohexanoyl, Ada: Adamantaneacetyl, Dansyl:
5-(dimethylamino)naphthalene-1-sulfonyl.
2031H.B. Kramer et al. / Biochimica et Biophysica Acta 1823 (2012) 2029–2037application of the Staudinger ligation [23] or 1,4-triazole formation
also known as "click" chemistry [24,25]. A more recent addition to
the arsenal of proteasome-directed probes has been the Belacostin A
derived dansyl-KF33955 probe [26]. This β-lactone containing probe
was used successfully in the labeling of β1, β2 and β5 subunits of
the 26S proteasome in HeLa cells as well as the 20S proteasome
from erythrocytes.4. Ubiquitin-derived probes
Ubiquitin derived ABPs [27,28] have been used for the proﬁling
of the active DUB population in cell lines, primary cells and tis-
sues [29]. Subsequently this concept has been extended to the
study of proteases speciﬁc for ubiquitin-like proteins (Ubls) [30].
A complex proteome such as a cell or tissue lysate is labeled by
incubation with ubiquitin probe, followed by SDS-PAGE separation
and immunoblotting against the epitope tag genetically encoded
in the probe construct. Thereby a read-out, which is dependent
on DUB abundance and activity, is obtained. This approach was
also extended to the investigation of cancer cell lines [29,31]
and patient biopsies [31]. Particularly fruitful was the study of in
vitro infection models of viral [32–35], parasitic [36,37] and bacte-
rial [38,39] pathogens. In this way previously unknown DUBs
encoded by pathogens were identiﬁed and other interactions of
pathogen encoded factors with the host ubiquitin proteasome sys-
tem were elucidated. DUB related pathogen–host interactions
have been reviewed in detail elsewhere [40–43]. Ubiquitin probes
have further enabled structural studies on DUB-ubiquitin com-
plexes [44]. In these investigations the crystallization and X-ray
diffraction of covalent adducts formed between enzyme and the
ubiquitin probe allowed insights into some of the molecular de-
terminants of interactions of DUBs with ubiquitylated substrates.These types of studies have also been successfully carried out
with complexes involving ubiquitin aldehyde [45–47] or ubiquitin
probes devoid of an epitope tag [48–50].
In addition to the utility of ubiquitin ABPs targeting Cys protease
DUBs, MS-based proteomics experiments of ubiquitin probes have
also been shown to retrieve other regulators of ubiquitylation, for ex-
ample Metalloprotease DUBs were retrieved under native pull-down
conditions [51]. This ﬁnding might be explained by the formation of
non-covalent complexes which can be enriched in immunoprecipita-
tions (IPs) under non-denaturing conditions. The targeting and re-
trieval of ubiquitin ligases by ubiquitin probes have also been
observed [52]. Usually the reduced nucleophilicity of Cys residues in
this enzyme class (when compared to Cys as part of the catalytic
triad in DUB proteases) results in strongly reduced capture. This can
apparently be compensated for to a certain extend by strong
C-terminal electrophiles conjugated to the Ub probes [52].
5. Activity-based probes allow enhanced inhibitor screening
In addition to the above-mentioned applications activity-based
proteomics probes have also enabled the development of pharma-
cologically active enzyme inhibitors. In one format, competition as-
says between an inhibitor candidate compound and the activity-
based probe can be performed in cell lysates. In this type of assay
format the competition between the small molecule inhibitor and
the probe leads to a reduced labeling proﬁle for the activity-based
probe. The loss of signal for labeling of speciﬁc target enzymes al-
lows assessment of the speciﬁcity of inhibition, while titration of
concentration ranges provides a measure of IC50 values for the re-
spective inhibitor. Several features make this type of assay format
particularly attractive: The approach represents a cell-based assay
in which treatment by the inhibitor candidate can be performed
on intact cells. In contrast to the majority of in vitro enzyme assays,
a range of active cellular enzymes can be assayed simultaneously.
This is only limited by the number of enzymes successfully labeled
by the activity-based probe and the representation of active en-
zymes in the cellular proteome. Quantiﬁable results can be
obtained using various readout formats including immunoblotting,
in-gel ﬂuorescence detection or IP followed by quantitative MS-
based proteomics.
Such an approach has been employed successfully for a number of
ABPs including in the identiﬁcation and characterization of selective
inhibitors of the proteasome [53,54], of cysteine proteases in the
DUB enzyme family [51] and serine hydrolases in the fatty acid
amide hydrolase class [55]. Promiscuous inhibitors can be tested in
this way in order to demonstrate their broad inhibition proﬁle [56]
and competition assays can be applied to the characterization of the
speciﬁcity of known drugs.
6. Characterization of the subunit speciﬁcity of
proteasome inhibitors
The development of novel cancer therapeutics is a prime example
where the success of bortezomib [16,57] for treatment of multiple
myeloma [58] has provided proof of concept for the value of interven-
tions targeting the ubiquitin proteasome system. The effects of
Bortezomib (PS-341) on the activity and composition of proteasomes
in multiple myeloma cells were investigated by labeling with
proteasome probe Ada-[125I]-Y-Ahx3L3VS demonstrating that the
inhibitor selectively targets β5 and β1 subunits (as well as
immunoproteasome subunits β5i and β1i) [57]. The corresponding
experiments were carried out in the presence or absence of cytokines,
which induce the formation of immunoproteasomes under conditions
that may be encountered in the bone marrow.
A similar characterization of the subunit speciﬁcity of proteasome
inhibition was also carried out for the orally active inhibitor NPI-0052
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competitive labeling with the proteasome probe Dansyl-Ahx3L3VS in-
dicated that the inhibitor targets the β1, β2 and β5 subunits. This re-
sult was consistent with the ﬁnding that cleavage of ﬂuorogenic
substrates showed inhibition of the CT-L, T-L and PGPH-L activities
of the proteasome.
In a comparable study the speciﬁcity of the three proteasome
inhibitors BzLLLCOCHO, Bortezomib (PS-341) and MG132 was
assessed by labeling with the cell permeable Dansyl-Ahx3L3VS
probe following treatment with individual inhibitors for 24 h [60].
This demonstrated clearly distinct labeling pattern of the proteolyt-
ically active proteasome subunits β1, β2 and β5 for the three inhib-
itors. The observed labeling patterns were positively correlated
with the inhibition of the CT-L, T-L and PGPH-L activities of the
proteasome by hydrolysis of suitable ﬂuorogenic substrates in the
presence of inhibitors.
The selective inhibition of the immunoproteasome subunit β1i
(LMP2) by synthetic Dihydroeponemycin analogs was demonstrated
by competitive labeling experiments in EL4 cells using biotin-
epoxomicin and biotin-eponemycin as a proteasome active site pro-
bes [61].
These examples highlight the value of utilizing active site-directed
probes in the development and characterization of proteasome inhib-
itors. This is enabled by their ability to provide a rapid assay of the
corresponding proteolytically active subunits in different cell types
and in the presence or absence of added competitive inhibitors the
speciﬁcities of which can thereby be assessed. This approach has
been informative to basic science as well as to the development of
lead compounds for novel therapeutics.
7. Competitive ubiquitin probe labeling for DUB
inhibitor development
Due to the large number of cellular DUBs there is a need for inno-
vative assay designs that allow assessment of DUB activity in a
cellular context. Competitive labeling with Ub probes provides char-
acterization of lead compounds in a cell culture model thereby pro-
viding valuable data for assessment of both compound potency and
selectivity of different DUBs relevant to a given cell type. A number
of DUB inhibitors have been characterized and developed into lead
compounds for medicinal chemistry programs. Generally the initial
hit has been obtained by high throughput screening (HTS) of com-
pound libraries followed by further optimization using structure–
activity relationships. It is noteworthy that many of the identiﬁed
lead compounds and inhibitors have the ability to covalently label
the active site cysteine residue present in the majority of DUBsN
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Fig. 3.Molecular structures of selected DUB and Ubl-protease inhibitors characterized by com
conjugate addition to Cys) are highlighted in blue and aryl halides which are capable of nu(Fig. 3). This may occur by conjugate addition, nucleophilic aromatic
substitution or disulﬁde bond formation depending on the chemistry
of the small molecule inhibitor.
One example of Ub probe labeling in the presence of a small mol-
ecule inhibitor has been the characterization of WP1130 as a partially
selective DUB inhibitor which induces aggresome formation and
tumor cell apoptosis by Kapuria et al. [62]. The selectivity of inhibition
for different members of the DUB family of enzymes was also investi-
gated by in vitro inhibition assays using UbAMC as a substrate in com-
bination with recombinant puriﬁed DUBs. The total cellular DUB
activity in lysates treated with inhibitors was tested by UbAMC hy-
drolysis. Labeling of treated versus untreated cell lysates with the
activity-based probe HAUbVS was performed in order to assess the
DUB inhibitory proﬁle of WP1130. In this assay format reduced label-
ing by the HAUbVS probe as detected in anti-HA immunoblotting of
lysates from cells treated with WP1130 was used as readout of selec-
tivity of DUB inhibition. A further focus of this work was the observa-
tion of accumulation of polyubiquitylated protein material upon
treatment with WP1130 despite a lack of inhibition of proteasome
activity.
Altun et al. described a more extensive application of activity-
based probes to the characterization and development of novel DUB
inhibitors [51]. In this study two DUB inhibitors, PR-619 and
P22077, were characterized by in vitro enzyme inhibition assays and
in cell culture models. Labeling of HEK293T cell lysates treated with
inhibitors at varying concentrations was performed with the
ubiquitin probes HAUbVME and HAUbBr2 to investigate DUB inhibi-
tion proﬁles. As a read-out of these assays immunoblotting against
HA-tag or speciﬁc DUBs of interest was carried out enabling a rapid
assessment of inhibitor speciﬁcity. In order to obtain an alternative
quantitative read-out format, anti-HA immunoprecipitation (IP) was
combined with identiﬁcation and label-free quantiﬁcation by mass
spectrometry based proteomics (Fig. 4). Using this approach, quanti-
tative data illustrating the degree of inhibition of 25 cellular DUBs
was obtained. These data were consistent with the in vitro enzyme
characterization data, demonstrating that PR-619 exhibits a broad in-
hibition proﬁle whereas P22077 is a selective inhibitor of USP7 and
USP47. Both USP7 and USP47 are considered oncology targets and
P22077 and related analogs are the subject of further development
as anti-cancer therapeutics [63,64].
Another application of Ub probe labeling for the development of
USP7 inhibitors was recently demonstrated by Reverdy et al. [65].
The screening hit HBX 19,818, which had been identiﬁed by high
throughput screening (HTS) of a compound library employing the
UbAMC assay, was characterized by HAUbVS labeling of HCT116
cells treated with increasing concentrations of the inhibitor. TheN
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showed reduced probe labeling of USP7 while leaving the competitive
labeling of other cellular DUBs unaffected. This result was consistent
with the in vitro enzyme inhibition data that also indicated a lack of
inhibition of other tested cysteine proteases, DUBs and Ubl speciﬁc
proteases, but the activity of HBX 19,818 towards the closely related
DUB USP47 was not discussed. The mechanism of inhibition was in-
vestigated by the authors and covalent labeling of the active site
Cys223 in USP7 was demonstrated, indicating that alkylation of this
residue leads to irreversible inactivation of the DUB. Furthermore
the cellular effects of the inhibitor were characterized as reduction
in cell proliferation, induction of apoptosis and G1 arrest in a dose-
dependent fashion.
A novel DUB inhibitor, b-AP15 was recently described by D'Arcy et
al. [66]. DUB proﬁling was carried out in the presence of ubiquitin
probe HAUbVS in HCT-116 cells after 3 h treatment with 1.0 μM in-
hibitor; demonstrating that USP14 and to a lesser extend UCHL5
were inhibited at this concentration. Treatment of cells with b-AP15
led to tumor cell apoptosis, which was independent of TP53 status.
Additionally an accumulation of high molecular weight Ub conjugates
and reduced levels of free ubiquitin were observed and ascribed to
the inhibition of the 19S associated DUBs USP14 and UCHL5. The au-
thors concluded that the compound does not act as a broad spectrum
DUB inhibitor at the concentration employed, rather it inhibits the
proteasome associated DUBs USP14 and UCH-L5. Thus, b-AP15150
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Fig. 4. Small molecule inhibitors affect DUBs in living cells; (A) Workﬂow of DUB inhibitio
described in [51]. (B) Workﬂow of proﬁling inhibitor capacity by immunoblot as describe
or 10 µM MG132, lysed and analyzed by SDS-PAGE and anti-HA immunoblotting.effectively inhibits proteasomal activity by inhibiting the DUBs that
process polyubiquitylated proteins prior to their engagement by the
proteasome.
This approach has utility for viral DUBs as well. The ubiquitin
probe HAUbVS has been successfully applied to demonstrate the se-
lectivity of inhibitor GRL0617 for the SARS Coronavirus protease and
isopeptidase Papain-like protease (Plpro) in Vero E6 cell lysate [67].
No change in labeling proﬁle was observed for cellular DUBs at inhib-
itor concentrations of up to 40 μM. In contrast, the labeling of added
Plpro was almost completely abolished at the same inhibitor
concentration.8. Utility of activity based proteomics in inhibitor characterization
outside the UPS
The usefulness of activity based probes (ABPs) in the development
and characterization of enzyme inhibitors has also been recognized in
ﬁelds outside the ubiquitin proteasome system. Below we describe
the advances made in the application of this concept to kinases and
phosphatases involved in protein phosphorylation. ABPs for the
targeting of kinases and phosphatases have received considerable at-
tention due to the central role of protein phosphorylation in cellular
signaling, protein translocation and ultimately its aberrations in
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Initial kinase probes have utilized ATP and ADP analogs as molec-
ular scaffolds thereby targeting the essential kinase co-factor in probe
design. Later approaches were built on modiﬁcation of known kinase
inhibitors of natural product origin or related to licensed drugs. Ki-
nase probes based on acyl phosphate ATP and ADP analogs which
lead to the transfer of a biotin to amino acid residues on the inter-
acting protein resulted in the labeling and identiﬁcation of a range
of kinases, ATPases, nucleotide biosynthesis-related and other pro-
teins [68]. The lack of selectivity for kinases in a cellular environment
is understandable given the wide range of proteins that utilize ATP as
a cofactor.
A tetramethylrhodamine-labeled Wortmannin analog AX7503
allowed labeling in mammalian cell lysates and readout of the assay
by in gel ﬂuorescence [69]. This ﬂuorescent kinase probe labeled
DNA dependent protein kinase (DNA-PK), phosphoinositide 3 kinase
and mammalian Polo-like kinase 1 (PLK1). Previously it had not
been appreciated that PLK1 is inhibited by Wortmannin at rele-
vant concentrations. Further Wortmannin derivatives labeled with
borondipyrromethene (BODIPY), tetramethylrhodamine or biotin
were prepared successfully [70]. It was shown that the BODIPY deriv-
ative is cell-permeable thereby enabled labeling of intact cells while
the biotin derivative allows isolation of labeled protein material
from cell lysates. In a follow-up study to this work Liu et al. also dem-
onstrated that Polo-like kinase 3 (PLK3) is a further molecular target
of Wortmannin as shown by competitive labeling between AX7503
and Wortmannin [71]. The labeling sites of AX7503 for both PLK1
and PLK3 were determined by tandem mass spectrometry and were
found to represent conserved lysine residues in the ATP binding site
of each of the kinases.
A bisindolylmaleimide motif was chosen as the scaffold for the de-
sign of a further kinase probe AX4697 [72]. This recognition motif
with a high afﬁnity for protein kinase C (PKC) was combined with a
chloroacetamide electrophile and a tetramethylrhodamine ﬂuo-
rophore. Successful labeling of α and β PKC in Jurkat cells was dem-
onstrated as well as loss of signal in staurosporine-pretreated cells.
A recent design of a probe for the Abelson Tyr kinase (Abl) was
based on the anti-cancer drug imatinib [73]. The reversible mode of
enzyme inhibition necessitated the incorporation of a photoreactive
benzophenone moiety or a dialdehyde motif for covalent labeling.
Detection was enabled by the incorporation of a terminal alkyne
into the structure allowing attachment of a rhodamine azide dye by
Cu(I) catalyzed triazole formation (click chemistry) [24,25]. Targeting
and detection of Abl kinase in the presence of added cell lysate
occurred, but the labeling efﬁciency diminished with increasing
amounts of lysate and the approach did not extend to labeling and
detection at endogenous levels.
The reversible and non-selective kinase inhibitor staurosporine
has also been utilized as the recognition motif in probe design by
several groups. In these probe designs covalent labeling is enabled
by incorporation of photoreactive phenylazide [74] or diazirine
[75] groups and irradiation by UV light. Enrichment of the trapped
proteins is performed by a further incorporated biotin moiety [74]
or a terminal alkyne for attachment of either a biotin group or a
ﬂuorophore for detection following the covalent capture by click
chemistry [75].
10. Phosphatase targeted activity-based probes
Activity based probes for protein tyrosine phosphatases (PTPs)
were developed on several scaffolds that allow mimicry of phos-
photyrosine motifs while incorporating reactive electrophiles for the
covalent capture of active phosphatases (Fig. 5). Several groups
exploited the generation of quinone methides for the generation of
reactive electrophiles for trapping of PTPs [76–79]. These aregenerated from substituted phenyl phosphates with benzylic ﬂuoride
substituents in ortho or para position. In a recent publication this
concept was extended to the design of the unnatural amino acid 2-
ﬂuoromethyl phosphotyrosine which was incorporated into peptides
by solid phase peptide synthesis (SPPS) [80]. In this way peptidic
activity based probes were produced based on known PTP target
sequences.
In earlier work Kumar et al. combined a minimal motif incorporat-
ing a bromomethyl phosphonate-substituted phenyl derivative
attached to either a ﬂuorophore or biotin for detection [81]. Success-
ful labeling of PTPs was demonstrated using both isolated enzymes
in vitro and in cell lysates of different cancer cell lines.
A further alternative approach exploited conjugate addition to
substituted aryl vinyl sulfonates and sulfones for the covalent labeling
of active PTPs [82]. This methodology was then applied to a structural
study of a covalent complex between the bacterial PTP YopH and its
mechanism based inhibitor.
Recently a novel probe design was implemented that enables
microscopy-based read out through the use of quenched activity
based probes [83]. In this strategy the quencher is released upon
quinone methide formation and reaction with the target enzyme.
The methodology has also been applied to one- and two-photon
imaging experiments.
In comparison, the targeting of Ser/Thr phosphatases by activity-
based probes has been less frequently realized. A successful example
is that of a microcystin derived probe which was prepared and
applied to the labeling and isolation of endogenous levels of Ser/Thr
protein phosphatases from Jurkat cell lysate [84].11. Characterization of kinase inhibitors by competition assays
and targeted proteomics
Acylphosphate kinase probes based on the ATP cofactor [68]
were used recently in an extensive study evaluating the speciﬁcity
proﬁles of a range of kinase inhibitors [85]. In this ‘in situ native ki-
nase proﬁling’ (KiNativ) approach, labeling of mammalian cell ly-
sates with the kinase probes was conducted in the presence or
2035H.B. Kramer et al. / Biochimica et Biophysica Acta 1823 (2012) 2029–2037absence of the respective inhibitor. The complex samples were then
digested with trypsin and biotinylated peptides enriched with
streptavidin resin. Following elution the captured peptides were
analyzed by quantitative proteomics experiments using a targeted
LC–MS2 approach. This detection method signiﬁcantly improved
the signal to noise ratios and allows detection of lower amounts
of analyte. Quantitative inhibition data for over 200 kinases with
six kinase inhibitors was obtained by this method. This approach
provides access to quantitative inhibition proﬁles that are not
easily obtained by other experimental approaches and exploits
the strengths of both activity-based probe proﬁling and targeted
mass spectrometry-based proteomics.
12. Future perspectives
The introduction of activity-based probes into the development of
enzyme inhibitors enables the assessment of compound selectivity in
a cellular context. This ideally complements more conventional in
vitro enzyme assays and allows implementation of this assay format
at an early stage in drug development. Furthermore competitive la-
beling experiments have greatly aided the deﬁnition of speciﬁcities
of inhibitors used in cellular research. New therapies in the UPS will
employ the manipulation of DUB activity in a highly selective manner
to achieve the desired outcomes. Therefore inhibition of selected in-
tracellular DUB activities will receive increasing attention as a strate-
gy for pharmacological intervention in disease. DUBs with a validated
role in oncology are expected to be the ﬁrst in line for future DUB in-
hibitors. Provided that challenges of developing speciﬁc inhibitors
with desirable compound proﬁles can be overcome, it is expected
that this will enable successful intervention in other pathologies
such as inﬂammatory diseases.
13. Summary
Activity-based probe designs have provided insights into mul-
tiple cellular pathways and have proven extremely valuable as
tools for the study of PTM conjugating and deconjugating en-
zymes. The investigation of the ubiquitin proteasome system has
beneﬁted from the development of probes for proteasomal prote-
olysis as well as deubiquitylating enzymes. Speciﬁcities and over-
lapping reactivities of ubiquitin-like proteases were investigated
by analogous Ubl probes. Inhibitor development has been facili-
tated through competitive labeling assays enabling elucidation of
inhibition proﬁles in a cellular environment. In addition, natural
product derived kinase probes have demonstrated the protein tar-
gets of these covalent inhibitors, indicating previously unknown
molecular targets and providing information in situations where
speciﬁcities of the respective compounds are not always fully elu-
cidated. The importance of access to selective inhibitors for basic
cell biology and drug development makes this area highly suited
for successful industry-academia collaborations.
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